UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

(Mark One)

☒

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~June 30, ~~2021~~2022

☐

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

NORTECH SYSTEMS INCORPORATED

Commission file number 0-13257

State of Incorporation: Minnesota

IRS Employer Identification No. 41-1681094

Executive Offices: 7550 Meridian Circle N., Suite # 150, Maple Grove, MN 55369

Telephone number: (952) 345-2244

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $.01 per share	NSYS	NASDAQ Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☐	Accelerated Filer ☐
Non-accelerated Filer ☒	Smaller Reporting Company ☒

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Number of shares of $.01 par value common stock outstanding at ~~November~~August 5, ~~2021~~2022 was ~~2,672,064.~~2,683,513.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

	~~PAGE~~
~~PART I - FINANCIAL INFORMATION~~
			PAGE
	Item 1	-	Financial Statements

			Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)	3

			Condensed Consolidated Balance Sheets	4

			Condensed Consolidated Statements of Cash Flows	5

			Condensed Consolidated Statements of Shareholders’ Equity	6

			Condensed Notes to Consolidated Financial Statements	~~7-16~~ 7-17

	Item 2	-	Management's Discussion and Analysis of Financial Condition And Results of Operations	~~17-22~~ 18-25

	Item 3	-	Quantitative and Qualitative Disclosures About Market Risk	22 26

	Item 4	-	Controls and Procedures	23 26

~~PART II - OTHER INFORMATION~~

PART II - OTHER INFORMATION
	~~Item 1~~	~~- Legal Proceedings~~	24

	Item ~~1A.~~ 1	- ~~Risk Factors~~	24 Legal Proceedings	27

	Item 2 1A.	- ~~Unregistered Sales of Equity Securities, Use of Proceeds~~	24 Risk Factors	27

	Item 3 2	- ~~Defaults on Senior~~	Unregistered Sales of Equity Securities, Use of Proceeds	24 27

	Item 4 3	- ~~Mine Safety Disclosures~~	24 Defaults on Senior Securities	27

	Item 5 4	- ~~Other Information~~	24 Mine Safety Disclosures	27

	Item 6 5	- ~~Exhibits~~	25 Other Information	27

~~SIGNATURES~~	26 Item 6	-	Exhibits	28

SIGNATURES				29

THREE MONTHS

NINE MONTHS

ENDED

ENDED

SEPTEMBER 30,

SEPTEMBER 30,

2021

2020

2021

2020

Net Sales
$ 29,452 $ 26,362 $ 81,706 $ 80,263

Cost of Goods Sold
21,411 24,400 68,519 72,336

Gross Profit
8,041 1,962 13,187 7,927

Operating Expenses

Selling Expenses
449 594 1,741 1,945
General and Administrative Expenses
2,045 2,480 7,247 6,654
Research and Development
141 0 348 0
Restructuring
23 0 319 0
Loss on Abandonment of Intangible Asset
560 0 560 0
Gain on Sale of Assets
(93 ) (3,821 ) (176 ) (3,821 )
Total Operating Expenses
3,125 (747 ) 10,039 4,778

Income From Operations
4,916 2,709 3,148 3,149

Other Expense

Interest Expense
(112 ) (126 ) (314 ) (526 )

Income Before Income Taxes
4,804 2,583 2,834 2,623

Income Tax Expense
1,247 612 646 638

Net Income
$ 3,557 $ 1,971 $ 2,188 $ 1,985

Net Income Per Common Share - Basic
$ 1.33 $ 0.74 $ 0.82 $ 0.75

Weighted Average Number of Common Shares Outstanding - Basic
2,665,682 2,657,530 2,662,066 2,657,530

Net Income Per Common Share - Diluted
$ 1.24 $ 0.73 $ 0.78 $ 0.74

Weighted Average Number of Common Shares Outstanding - Diluted
2,880,073 2,703,029 2,806,958 2,670,984

Other Comprehensive Income

Foreign Currency Translation Gain (Loss)
(5 ) 96 20 54
Comprehensive Income, Net of Tax
$ 3,552 $ 2,067 $ 2,208 $ 2,039

	THREE MONTHS ENDED						SIX MONTHS ENDED
	JUNE 30,						JUNE 30,
	2022			2021			2022			2021

Net Sales	$	32,518		$	30,182		$	63,229		$	52,254

Cost of Goods Sold		27,514			26,597			54,181			47,108

Gross Profit		5,004			3,585			9,048			5,146

Operating Expenses
Selling Expenses		960			571			1,793			1,292
General and Administrative Expenses		2,668			2,418			5,397			5,214
Research and Development Expenses		351			207			679			207
Restructuring Charges		0			77			0			296
Gain on Sale of Assets		0			(94	)		(15	)		(94	)

Total Operating Expenses		3,979			3,179			7,854			6,915

Income (Loss) From Operations		1,025			406			1,194			(1,769	)

Other Expense
Interest Expense		(117	)		(116	)		(215	)		(202	)

Income (Loss) Before Income Taxes		908			290			979			(1,971	)

Income Tax Expense (Benefit)		189			111			122			(596	)

Net Income (Loss)	$	719		$	179		$	857		$	(1,375	)

Net Income (Loss) Per Common Share:

Basic (in dollars per share)	$	0.27		$	0.07		$	0.32		$	(0.52	)
Weighted Average Number of Common Shares Outstanding - Basic (in shares)		2,683,131			2,658,926			2,681,931			2,659,028

Diluted (in dollars per share)	$	0.25		$	0.06		$	0.30		$	(0.52	)
Weighted Average Number of Common Shares Outstanding - Diluted (in shares)		2,886,755			2,767,991			2,879,216			2,659,028

Other comprehensive (loss) income
Foreign currency translation		(244	)		58			(239	)		24
Comprehensive income (loss), net of tax	$	475		$	237		$	618		$	(1,351	)

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

	SEPTEMBER 30,			DECEMBER 31,			JUNE 30			DECEMBER 31,
	2021				2020¹		2022			2021⁽¹⁾
	(Unaudited)						(Unaudited)
ASSETS
Current Assets
Cash	$	444		$	352		$	944		$	643
Restricted Cash		999			3,212			231			1,582
Accounts Receivable, less allowances of $361 and $343		13,931			15,625
Accounts Receivable, less allowances of $297 and $328								16,468			14,548
Employee Retention Credit Receivable		5,209			0			5,209			5,209
Inventories, Net		20,643			13,917			22,970			19,434
Contract Assets		8,145			5,899			9,070			8,698
Income Taxes Receivable		0			547
Prepaid Expenses and Other Current Assets		1,763			1,485			1,563			1,660
Total Current Assets		51,134			41,037			56,455			51,774

Property and Equipment, Net		5,803			6,426			6,144			5,833
Operating Lease Assets		9,052			8,998			8,420			8,983
Other Intangible Assets, Net		524			1,173			471			501
Total Assets	$	66,513		$	57,634		$	71,490		$	67,091

LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities
Current Maturities of Line of Credit	$	6,009		$	0
Current Maturities of Long-Term Debt		3,198			1,204
Current Portion of Finance Lease Obligations		613			660		$	447		$	601
Current Portion of Operating Lease Obligations		1,023			688			1,099			1,043
Accounts Payable		14,140			11,239			14,108			12,710
Accrued Payroll and Commissions		4,407			2,870			3,961			4,045
Other Accrued Liabilities		3,323			2,875			4,675			3,907
Income Tax Payable		168			0
Total Current Liabilities		32,881			19,536			24,290			22,306

Long-Term Liabilities
Long-Term Line of Credit		0			3,328
Long-Term Debt, Net		3,039			5,865
Long Term Line of Credit								11,360			8,959
Long Term Finance Lease Obligations, Net		707			1,152			734			916
Long-Term Operating Lease Obligations, Net		8,744			8,889			8,103			8,695
Other Long-Term Liabilities		106			146			100			104
Total Long-Term Liabilities		12,596			19,380			20,297			18,674

Total Liabilities		45,477			38,916			44,587			40,980

Commitments and Contingencies

Shareholders' Equity
Preferred Stock, $1 par value; 1,000,000 Shares Authorized: 250,000 Shares Issued and Outstanding		250			250			250			250
Common Stock - $0.01 par value; 9,000,000 Shares Authorized: 2,672,064 and 2,659,628 Shares Issued and Outstanding, respectively		27			27
Common Stock - $0.01 par value; 9,000,000 Shares Authorized: 2,683,513 and 2,672,064 Shares Issued and Outstanding, respectively								27			27
Additional Paid-In Capital		15,926			15,816			16,136			15,962
Accumulated Other Comprehensive Loss		(17	)		(37	)
Accumulated Other Comprehensive (Income) Loss								(183	)		56
Retained Earnings		4,850			2,662			10,673			9,816
Total Shareholders' Equity		21,036			18,718			26,903			26,111
Total Liabilities and Shareholders' Equity	$	66,513		$	57,634		$	71,490		$	67,091

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

1⁽¹⁾ The condensed consolidated balance sheet at December 31, ~~2020~~2021 has been derived from the audited financial statements at that date

NINE MONTHS ENDED

SEPTEMBER 30,

2021

2020

Cash Flows From Operating Activities

Net Income
$ 2,188 $ 1,985
Adjustments to Reconcile Net Income to Net Cash

(Used In) Provided by Operating Activities

Depreciation and Amortization
1,506 1,703
Compensation on Stock-Based & Equity Awards
201 151
Change in Accounts Receivable Allowance
18 158
Change in Inventory Reserves
(959 ) 398
Loss on Abandonment of Intangible Asset
560 0
Gain on Disposal of Property and Equipment
(176 ) (3,821 )
Changes in Current Operating Items

Accounts Receivable
1,686 2,430
Employee Retention Credit Receivable
(5,209 ) 0
Inventories
(5,755 ) (567 )
Contract Assets
(2,246 ) 325
Prepaid Expenses and Other Current Assets
(276 ) 858
Income Taxes
708 0
Accounts Payable
2,901 (2,808 )
Accrued Payroll and Commissions
1,537 (621 )
Other Accrued Liabilities
464 (290 )
Net Cash Used In Operating Activities
(2,852 ) (99 )
Cash Flows from Investing Activities

Proceeds from Sale of Property and Equipment
626 6,019
Purchase of Intangible Asset
(49 ) (25 )
Purchases of Property and Equipment
(1,198 ) (397 )
Net Cash (Used In) Provided By Investing Activities
(621 ) 5,597
Cash Flows from Financing Activities

Net Change in Line of Credit
2,681 (7,542 )
Proceeds from Long-term Debt
0 6,077
Principal Payments on Long-Term Debt
(873 ) (2,567 )
Principal Payments on Finance Leases
(492 ) (432 )
Stock Option Exercises
36 0
Net Cash Provided By (Used In) Financing Activities
1,352 (4,464 )

Net Change in Cash
(2,121 ) 1,034
Cash - Beginning of Period
3,564 660

Cash - Ending of Period
$ 1,443 $ 1,694

Reconciliation of cash and restricted cash reported within the condensed consolidated balance sheets

Cash
$ 444 $ 328
Restricted Cash
999 1,366
Total cash and restricted cash reported in the condensed consolidated statements of cash flows
$ 1,443 $ 1,694

Supplemental Disclosure of Cash Flow Information:

Cash Paid During the Period for Interest
$ 220 $ 526
Cash Paid (Refunded) During the Period for Income Taxes
$ (114 ) $ 262

Supplemental Noncash Investing and Financing Activities:

Property and Equipment Purchases in Accounts Payable
$ 0 $ 6
Property Acquired under Operating Lease
$ 858 $ 4,685
Equipment Acquired under Finance Lease
$ 0 $ 395

	SIX MONTHS ENDED
	JUNE 30,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)	$	857		$	(1,375	)
Adjustments to Reconcile Net Income (Loss) to Net Cash
Provided By (Used In) Operating Activities:
Depreciation and Amortization		967			967
Compensation on Stock-Based Awards		141			160
Change in Accounts Receivable Allowance		(31	)		116
Change in Inventory Reserves		(103	)		(655	)
Gain on Sale of Assets		(15	)		(94	)
Changes in Current Operating Items
Accounts Receivable		(1,986	)		(1,153	)
Inventories		(3,540	)		(3,719	)
Contract Assets		(372	)		(1,019	)
Prepaid Expenses and other Curent Assets		89			(286	)
Income Taxes		(63	)		(757	)
Accounts Payable		1,346			1,576
Accrued Payroll and Commissions		(84	)		686
Other Accrued Liabilities		854			120
Net Cash Used In Operating Activities		(1,940	)		(5,433	)

CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from Sale of Property and Equipment		15			94
Purchase of Intangible Asset		(41	)		(77	)
Purchases of Property and Equipment		(1,182	)		(659	)
Net Cash Used In Investing Activities		(1,208	)		(642	)

CASH FLOWS FROM FINANCING ACTIVITIES
Net Change in Line of Credit		2,394			4,339
Principal Payments on Long-Term Debt		0			(249	)
Principal Payments on Financing Leases		(336	)		(326	)
Debt Issuance Costs		7			0
Stock Option Excercises		33			0
Net Cash Provided By Financing Activities		2,098			3,764

Net Change in Cash and Cash Equivalents		(1,050	)		(2,311	)
Cash and Cash Equivalents - Beginning of Period		2,225			3,564
Cash and Cash Equivalents - End of Period	$	1,175		$	1,253

Reconciliation of cash and restricted cash reported within the consolidated balance sheets
Cash	$	944		$	661
Restricted Cash		231			592
Total Cash and restricted cash reported in the consolidated statements of cash flows	$	1,175		$	1,253
Supplemental Disclosure of Cash Flow Information:
Cash Paid During the Period for Interest	$	198		$	81
Cash Paid During the Period for Income Taxes		20			156

Supplemental Noncash Investing and Financing Activities:
Property and Equipment Purchases in Accounts Payable		52			0
Property Acquired Under Operating Lease		0			858

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

	Preferred		Common		Additional Paid-In Capital		Accumulated Other Comprehensive Loss			Retained Earnings		Total Shareholders' Equity									Accumulated
BALANCE JUNE 30, 2020	$	250	$	27	$	15,823	$	(299	)	$	4,222	$	20,023
																			Additional		Other						Total
															Preferred		Common		Paid-In		Comprehensive			Retained			Shareholders'
															Stock		Stock		Capital		Loss			Earnings			Equity

BALANCE MARCH 31, 2021															$	250	$	27	$	15,837	$	(71	)	$	1,108		$	17,151
Net Income		0		0		0		0			1,971		1,971			0		0		0		0			179			179
Foreign currency translation adjustment		0		0		0		96			0		96			0		0		0		58			0			58
Compensation on stock-based awards		0		0		36		0			0		36			0		0		25		0			0			25

BALANCE SEPTEMBER 30, 2020	$	250	$	27	$	15,859	$	(203	)	$	6,193	$	22,126
BALANCE JUNE 30, 2021															$	250	$	27	$	15,862	$	(13	)	$	1,287		$	17,413

BALANCE DECEMBER 31, 2019	$	250	$	27	$	15,748	$	(257	)	$	4,208	$	19,976
BALANCE DECEMBER 31, 2020															$	250	$	27	$	15,816	$	(37	)	$	2,662		$	18,718
Net Loss																0		0		0		0			(1,375	)		(1,375	)
Foreign currency translation adjustment																0		0		0		24			0			24
Compensation on stock-based awards																0		0		46		0			0			46

BALANCE JUNE 30, 2021															$	250	$	27	$	15,862	$	(13	)	$	1,287		$	17,413

BALANCE MARCH 31, 2022															$	250	$	27	$	16,043	$	61		$	9,954		$	26,335
Net Income		0		0		0		0			1,985		1,985			0		0		0		0			719			719
Foreign currency translation adjustment		0		0		0		54			0		54			0		0		0		(244	)		0			(244	)
Compensation on stock-based awards		0		0		111		0			0		111			0		0		93		0			0			93

BALANCE SEPTEMBER 30, 2020	$	250	$	27	$	15,859	$	(203	)	$	6,193	$	22,126
BALANCE JUNE 30, 2022															$	250	$	27	$	16,136	$	(183	)	$	10,673		$	26,903


BALANCE JUNE 30, 2021	$	250	$	27	$	15,862	$	(12	)	$	1,293	$	17,420
BALANCE DECEMBER 31, 2021															$	250	$	27	$	15,962	$	56		$	9,816		$	26,111
Net Income		0		0		0		0			3,557		3,557			0		0		0		0			857			857
Foreign currency translation adjustment		0		0		0		(5	)		0		(5	)		0		0		0		(239	)		0			(239	)
Stock option exercises		0		0		36		0			0		36			0		0		33		0			0			33
Compensation on stock-based awards		0		0		28		0			0		28			0		0		141		0			0			141

BALANCE SEPTEMBER 30, 2021	$	250	$	27	$	15,926	$	(17	)	$	4,850	$	21,036

BALANCE DECEMBER 31, 2020	$	250	$	27	$	15,816	$	(37	)	$	2,662	$	18,718
Net Income		0		0		0		0			2,188		2,188
Foreign currency translation adjustment		0		0		0		20			0		20
Stock option exercises		0		0		36		0			0		36
Compensation on stock-based awards		0		0		74		0			0		74

BALANCE SEPTEMBER 30, 2021	$	250	$	27	$	15,926	$	(17	)	$	4,850	$	21,036
BALANCE JUNE 30, 2022															$	250	$	27	$	16,136	$	(183	)	$	10,673		$	26,903

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

The accompanying unaudited condensed consolidated financial statements for the interim periods have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the financial information and footnotes required by GAAP for complete financial statements, although we believe the disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year or for any other interim period. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In preparing these condensed consolidated financial statements, we have made our best estimates and judgments of certain amounts included in the condensed consolidated financial statements, giving due consideration to materiality. Changes in the estimates and assumptions used by us could have a significant impact on our financial results, since actual results could differ from those estimates.

The condensed consolidated financial statements include the accounts of Nortech Systems Incorporated and its ~~wholly-owned~~wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Our revenue is comprised of product, engineering services and repair services. All revenue is recognized when the Company satisfies its performance obligation(s) under the contract by transferring the promised product or service to our customer either when (or as) our customer obtains control of the product or service, with the majority of our revenue being recognized over time including goods produced under contract manufacturing agreements and services revenue. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation. The majority of our contracts have a single performance obligation. Revenue is recorded net of returns, allowances and customer discounts. Our net sales for services were less than 10% of our total sales for all periods presented, and accordingly, are included in net sales in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). Sales, value add, and other taxes collected from customers and remitted to governmental authorities are accounted for on a net (excluded from revenues) basis. Shipping and handling costs charged to our customers are included in net sales, while the corresponding shipping expenses are included in cost of goods sold.

~~Following is the status of all stock options as of~~ ~~September 30, 2021:~~

In May 2017, the shareholders approved the 2017 Stock Incentive Plan which authorized the issuance of ~~400,000~~350,000 shares. ~~There~~An additional 50,000 and 175,000 shares were ~~additional shares~~ authorized by the shareholders in March 2020 ~~totaling 50,000~~ and in May ~~2021~~2022, ~~totaling 75,000.~~respectively.

We granted 0 and 21,000 market condition options to our Chief Executive Officer during the three and six months ended June 30, 2022, respectively. The market condition options vest if certain stock prices are exceeded between February 27, 2024 and February 27, 2028. We granted 13,000 and 66,000 service-based options during the three and six months ended June 30, 2022, respectively. Total option grants for the three and six months ended June 30, 2022 were 13,000 and 108,000, respectively. There were ~~27,000 and 11,300~~3,000 stock options granted during the ~~nine~~six months ended ~~September~~June 30, ~~2021~~ 2021.~~and~~ ~~2020,~~ ~~respectively.~~

Total compensation expense related to stock options was $64 and $106 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022, ~~was $28 and $74,~~ respectively. Total compensation expense related to stock options was $25 and $46 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021. ~~was $36 and $111, respectively.~~ As of ~~September~~June 30, ~~2021,~~2022, there was ~~$320~~$851 of unrecognized compensation which will vest over the next ~~3.12~~3.90 years.

During the three and six months ended June 30, 2022, we granted 3,000 and 21,000 restricted stock units (“RSUs”), respectively, under our 2017 Stock Incentive Plan to non-employee directors which vest over two years. There were no RSUs outstanding prior to the six months ended June 30, 2022. Total compensation expense related to the RSUs were $29 and $35 for the three and six months ended June 30, 2022, respectively. There was 0 compensation expense related to RSUs for the three and six months ended June 30, 2021. Total unrecognized compensation expense related to the RSUs was $218, which will vest over the next 1.74 years. The RSUs granted in the six months ended June 30, 2022 had an average grant price of $12.00 per share with a weighted average remaining contractual term of 9.73 years. NaN RSUs vested during the six months ended June 30, 2022.

In November 2010, the Board of Directors adopted the Nortech Systems Incorporated Equity Appreciation Rights Plan (“2010 Plan”). The total number of Equity Appreciation Right Units (“Units”) that can be issued under the 2010 Plan shall not exceed an aggregate of 1,000,000 Units as amended and restated on March 11, 2015. ~~During the~~ ~~nine~~ ~~months ended~~ ~~September 30, 2021~~ ~~and~~ ~~2020,~~ ~~there~~There were no ~~Units granted. We recognized $13 and $127~~units granted during the six months ended June 30, 2022 or June 30, 2021.

The 100,000 units outstanding at December 31, 2021 were paid on March 29, 2022. As ofJune 30, 2022, there are 0 units outstanding. Total compensation expense inrelated to the vested outstanding Units based on the estimated appreciation over their remaining terms was $100 and $114 for the three and ~~nine~~six months ended ~~September~~June 30, 2021, respectively. ~~Compensation expense was approximately $40 for both the~~ ~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~September 30, 2020.~~ ~~The current liability recorded for the Units at~~ ~~September 30, 2021~~ is ~~$235.~~

Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Dilutive net income (loss) per common share assumes the exercise and issuance of all potential common stock equivalents in computing the weighted-average number of common shares outstanding, unless their effect is antidilutive. All stock options and restricted stock units, while outstanding, are considered common stock equivalents.

For the three and ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, stock options of ~~214,391~~203,625 and ~~144,892,~~197,285, respectively were included in the computation of diluted net income per common share ~~amount~~ as their impact were dilutive. For the three ~~and~~ ~~nine~~months ended ~~September~~June 30, ~~2020,~~2021, stock options of ~~45,326 and 21,220, respectively,~~109,065 were included in the computation of diluted net income per common share. For the six months ended June 30, 2021, all stock options are deemed to be antidilutive and therefore, were not included in the computation of net income per common share ~~as their impact were dilutive.~~amount.

We had outstanding stock options totaling 45,878 and RSUs totaling 19,114 that are not considered in the computation of diluted net income per share as their effect would have been anti-dilutive for the three months ended June 30, 2022. We had average outstanding stock options totaling 48,895 and RSUs totaling 20,057 that are not considered in the computation of diluted net income per share as their effect would have been anti-dilutive for the six months ended June 30, 2022. Outstanding stock options totaling 622 are not considered in the computation of diluted net income per share for the three months ended June 30, 2021.

Cash and cash equivalents classified as restricted cash on our ~~condensed~~ consolidated balance sheets are restricted as to withdrawal or use under the terms of certain contractual agreements. As of June 30, 2022 we had outstanding letters of credit for $400. Restricted cash as of June 30, 2022 was $231. The ~~September~~June 30, ~~2021~~2022 restricted cash balance included lockbox deposits that are temporarily restricted due to timing at the period end. The lockbox deposits are applied against our line of credit the next business day.

Credit is extended based upon an evaluation of the customer’s financial condition and, while collateral is not required, the Company periodically receives ~~customer deposits.~~surety bonds that guarantee payment. Credit terms are consistent with industry standards and practices. ~~The amounts of trade~~Trade accounts receivable have been reduced by an allowance for doubtful accounts of ~~$361~~$297 at ~~September~~June 30, ~~2021~~2022 and ~~$343~~$328 at December 31, ~~2020.~~2021.

~~We qualified for Employee Retention Credits on qualified wages paid in the~~ ~~first~~ ~~and~~ ~~second~~ ~~quarters of~~ ~~2021~~ and filed for both credits as of the date of this filing. We recognize government grants for which there is a reasonable assurance of compliance with grant conditions and receipt of credits. During the ~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~September 30, 2021,~~ there was $5,209 related to Employee Retention Credits recognized as a reduction of the associated costs within cost of goods sold of $4,670, selling of $125, and general and administrative expenses of $414 on the consolidated statements of operations and within Employee Retention Credits Receivable on the condensed consolidated balance sheets.

~~The CARES Act allowed for the deferral of the employer portion of social security taxes incurred through the end of calendar~~ ~~2020.~~ ~~As of~~ ~~September 30, 2021,~~ ~~there was $1,158 of social security tax payments deferred, of which~~ ~~50%~~ ~~are required to be remitted by~~ ~~December 2021~~ ~~and the remaining~~ ~~50%~~ by ~~December 2022.~~ ~~The deferred amounts are recorded within accrued payroll and commissions on the condensed consolidated balance sheets.~~

Inventories are stated at the lower of average cost ((which approximates first-in, first~~-out method)~~ out) or net realizable value. Costs include material, labor, and overhead required in the warehousing and production of our products. Inventory reserves are maintained for the estimated value of the inventories that may have a lower value than stated or quantities in excess of future production needs.

Property and equipment are stated at cost less accumulated depreciation. Additions, improvements and major renewals are capitalized, while maintenance and minor repairs are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in operations. Leasehold improvements are depreciated over the shorter of their estimated useful lives or their remaining lease terms. All other property and equipment are depreciated by the straight-line method over their estimated useful lives.

Other intangible assets at ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020~~2021 are as follows:

~~In the~~ ~~three~~ ~~months ended~~ ~~September 30, 2021,~~ ~~we determined the fair value of the Devicix tradename was more likely than~~ ~~not~~ be ~~zero~~ ~~based on management’s best estimate and recognized a $560 loss on abandonment of intangible assets.~~

Intangible assets are amortized on a straight-line ~~bases~~basis over their estimated useful lives. The ~~weighted average~~weighted-average remaining amortization period of our in-use intangible ~~assets~~asset is ~~3.0~~2.0 years. Patents are not being amortized as they are in process and a patent has not yet been received.

Amortization expense of finite life intangible assets for the three and ~~nine~~six months ended ~~September~~June 30, 2022 was $35 and $71, respectively. Amortization expense for the three and six months ended June 30, 2021 was ~~$45~~$46 and ~~$139,~~$92, respectively.

Estimated future annual amortization expense (not including ~~projects~~the patents in process) related to these assets is approximately as ~~follows (in thousands):~~

Certain reclassifications have been made to the prior year’s consolidated financial statements to enhance comparability with the current year’s financial statements. As a result, certain line items have been amended in the statement of operations. Comparative figures have been adjusted to conform to the current year’s presentation.

In June 2016, the FASB issued ASU ~~No.~~2016-13, ~~“Financial Instruments - Credit Losses (ASC~~ ~~326~~): Measurement of Credit Losses on Financial ~~Instruments,” which amends the~~Instruments. This guidance ~~on the impairment of financial instruments. The amendments in this update removes the thresholds that entities apply to measure~~introduces a new model for recognizing credit losses on financial instruments measured at amortized cost, such as loans, trade receivables, reinsurance recoverables, off-balance-sheet credit exposures, and held-to-maturity securities. Under current U.S. GAAP, entities generally recognize credit losses when it is probable that the loss has been incurred. The guidance removes all current recognition thresholds and introduces the newbased on an estimate of current expected credit ~~loss (“CECL”) model which will require~~losses. The ASU also provides updated guidance regarding the impairment of available-for-sale debt securities and includes additional disclosure requirements. The new guidance is effective for public business entities ~~to recognize an allowance for credit losses for~~that meet the ~~difference between the amortized cost basis~~definition of a ~~financial instrument~~Smaller Reporting Company as defined by the SEC for interim and the amount of amortized cost that an entity expects to collect over the instrument’s contractual life. The new CECL model is based upon expected losses rather than incurred losses. The amendments in this update are effective forannual periods beginning after December 15, ~~2022;~~2022. ~~early~~Early adoption is permitted. We are currently evaluating the impact of this ~~guidance on our financial condition and results of operations.~~

In ~~March 2020,~~ ~~the FASB issued ASU~~ ~~2020~~-~~04,~~ ~~Reference Rate Reform. ASU~~ ~~2020~~-04 provides optional guidance for a limited period of time to ease potential accounting impact associated with transitioning away from reference rates that are expected to be discontinued, such as LIBOR. The amendments in this ASU apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued. The amendments in ASU ~~2020~~-04 ~~can be adopted as of~~ ~~March 12, 2020~~ ~~and are effective through~~ ~~December 31, 2022.~~ ~~We do~~ ~~not~~ ~~currently have any contracts that have been changed to a new reference rate, we will continue to evaluate our contracts and the effects of this~~ standard on our ~~condensed~~ consolidated financial statements ~~prior to adoption.~~

Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. With regard to cash, we maintain our excess cash balances in checking accounts at primarily two financial institutions, one in the United States and one in China. The account in the United States may at times exceed federally insured limits. Of the ~~$1,443~~$1,175 in cash and restricted cash at ~~September~~June 30, ~~2021,~~2022, approximately ~~$378~~$691 and $5$54 was held at banks located in China and Mexico, respectively. We grant credit to customers in the normal course of business and do not require collateral on our accounts receivable.

We have certain customers whose revenue individually represented 10% or more of net sales, or whose accounts receivable balances individually represented 10% or more of total accounts receivable. ~~For the~~ ~~three~~ ~~months ended~~ ~~September 30, 2021,~~ ~~two~~ ~~customers accounted for 36% of net sales. For the~~ ~~three~~ ~~months ended~~ ~~September 30, 2020,~~ ~~one~~ ~~customer accounted for 23% of net sales. At~~ ~~September 30, 2021~~ ~~and~~ ~~2020,~~~~one~~One customer accounted for ~~26%~~28% and ~~23%~~26% of net sales ~~respectively~~ for the three and six months ended June 30, 2022, respectively. One customer accounted for 25% and 27% of net sales for the three and six months ended June 30, 2021, respectively.

At ~~September~~June 30, ~~2021,~~2022, 2two customers represented approximately ~~36%~~37% of our total accounts receivable. At December 31, ~~2020,~~2021, one customer represented approximately ~~20%~~19% of our total accounts receivable.

Export sales represented approximately 4% of net sales for both the three and six months ended June 30, 2022. Export sales represented approximately 2% and 3% of net sales for the three ~~months ended~~ ~~September 30, 2021~~ and ~~2020.~~ ~~Export sales represented 3% of net sales for the~~ ~~nine~~six months ended ~~September~~June 30, 2021 ~~and~~ ~~2020.~~respectively.

Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or providing services. As such, revenue is recorded net of returns, allowances and customer discounts. Sales, value add, and other taxes collected from customers and remitted to governmental authorities are accounted for on a net (excluded from revenues) basis. Shipping and handling costs are included in cost of goods sold.

The majority of our revenue is derived from the transfer of goods produced under contract manufacturing agreements which have no alternative use and we have an enforceable right to payment for our performance completed to date. Our performance obligations within our contract manufacturing agreements are generally satisfied over time as the goods are produced based on customer specifications and we have an enforceable right to payment for the goods produced. If these requirements are not met, the revenue is recognized at a point in time, generally upon shipment. Revenue under contract manufacturing agreements that was recognized over time accounted for approximately 74% of our revenue for both the three and six months ended June 30, 2022 and 82% and ~~80%~~79% of our revenue for the three and ~~nine~~six months ended ~~September~~June 30, 2021,~~respectively and for approximately 80% and 84% of our revenue for the~~ ~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~September 30, 2020,~~ respectively. Revenues under these agreements are generally recognized over time using an input measure based upon the proportion of actual costs incurred.

Accounting for contract manufacturing agreements involves the use of various techniques to estimate total revenue and costs. We estimate profit on these agreements as the difference between total estimated revenue and expected costs to complete the performance obligation within the terms of the agreement and recognize the respective profit as the goods are produced. The estimates to determine the profit earned on the performance obligation are based on anticipated selling prices and historical cost of goods sold and represent our best judgement at the time. Changes in judgements on these above estimates could impact the timing and amount of revenue recognized with a resulting impact on the timing and amount of associated profit.

On occasion our customers provide materials to be used in the manufacturing process and the fair value of the materials is included in revenue as noncash consideration at the point in time when the manufacturing process commences along with the same corresponding amount recorded as cost of goods sold. The inclusion of noncash consideration has no impact on overall profitability.

Contract assets, recorded as such in the Condensed Consolidated Balance ~~Sheet,~~Sheets, consist of unbilled amounts related to revenue recognized over time. Significant changes in the contract assets balance during the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 was as follows (in thousands):

We expect substantially all the remaining performance obligations for the contract assets recorded as of ~~September~~June 30, ~~2021,~~2022 to be transferred to receivables within 90 days, with the majority of any remaining amounts to be transferred within 180 days. We bill our customers upon shipment with payment terms of up to 120 days.

The following tables summarize our net sales by ~~market for the~~ ~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~September 30, 2021~~ ~~and~~ ~~2020~~ ~~(in thousands):~~market:

We have a credit agreement with Bank of America which was entered into on June 15, 2017 ~~which was amended~~ ~~five~~ ~~separate occasions on~~ ~~December 29, 2017,~~ ~~August 13, 2019,~~ ~~November 12, 2019,~~ ~~August 27, 2020,~~ ~~and~~ ~~December 1, 2020~~ and provides for a line of credit arrangement of $16,000 that expires on June 15, ~~2022.~~ 2026.~~The credit arrangement also has a $5,000 real estate term note outstanding with a maturity date of~~ ~~June 15, 2022.~~ ~~The line of credit is classified as current on~~

Under the ~~consolidated balance sheet as of~~ ~~September 30, 2021,~~ ~~however we expect to extend the agreement past~~ ~~June 15, 2022.~~

~~Under the~~amended Bank of America credit agreement ~~both~~ signed December 31, 2021, the line of credit ~~and real estate term notes are~~is subject to variations in the ~~LIBOR~~Bloomberg Short-Term Bank Yield (BSBY) index rate. Our line of credit bears interest at a weighted-average interest rate of ~~3.4%~~3.9% and ~~4.0%~~3.5% as of ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, respectively. We had borrowings on our line of credit of ~~$6,009~~$11,410 and ~~$3,328~~$9,016 outstanding as of ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, respectively. ~~Borrowing on the real estate term note was $197 and $1,071 as of~~ ~~September 30, 2021~~ ~~and~~ ~~December 31, 2020,~~ ~~respectively. Payment on the real estate term note is approximately $41 per month.~~ There are no subjective acceleration clauses under the credit agreement that would accelerate the maturity of our outstanding borrowings. The line of credit is shown net of debt issuance costs of $50 and $58 on the consolidated balance sheet for the periods ended June 30, 2022 and December 31, 2021, respectively.

The line of credit ~~and real estate term notes~~ with Bank of America ~~contain~~contains certain covenants which, among other things, require us to adhere to regular reporting requirements, abide by annual shareholder dividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures. ~~The availability under our line is subject to borrowing base requirements, and advances are at the discretion of the lender. The line of credit is secured by substantially all of our assets.~~

The Bank of America Credit Agreement provides for, among other things, a Fixed Charge Coverage Ratio of not less than 1.0 to 1.0 for the twelve months ended ~~December 31, 2020~~ ~~and~~at each Fiscal Quarter end ~~thereafter~~ subject only during a trigger period commencing when our availability under our line is less than $2,000 until availability is above that amount for 30 ~~days due to amendment to our agreement dated~~days. As of June 30, 2022 the Company was in ~~December~~ of ~~2020.~~ ~~The Company met the covenants for the period ended~~ ~~September 30, 2021.~~compliance with its covenants.

~~The availability under the line is subject to borrowing base requirements, and advances are at the discretion of the lender.~~ At ~~September~~June 30, ~~2021,~~2022, we had unused availability under our line of credit of ~~$5,762,~~$4,190 supported by our borrowing base. The line is secured by substantially all of our assets.

On ~~April 15, 2020,~~ we entered into the Promissory Note, which provides for an unsecured loan of $6,077 pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act and applicable regulations (the “CARES Act”) of which funds were received on ~~April 22, 2020.~~ ~~The Promissory Note has a term of~~ 2 ~~years with a~~ 1% ~~per annum interest rate. Payments are deferred for~~ 10 ~~months after the end of the Promissory Note covered period (which is defined as~~ 24 ~~weeks after the date of the loan) and we can apply for forgiveness of the Promissory Note after~~ 60 days. Forgiveness of the Promissory Note will be determined in accordance with the provisions of the Cares Act and applicable regulations. Any principal and interest amounts outstanding after the determination of amounts forgiven will be repaid on a monthly basis. We applied for forgiveness of the Promissory Note in In the ~~third~~first quarter of ~~2021.~~2022, ~~We continue~~we amended our credit agreement to ~~treat this Promissory Note~~include the Employee Retention Credit Receivable as ~~debt until forgiveness is granted, if forgiven.~~security in our line of credit which improved our unused availability.

We have operating leases for certain manufacturing sites, office space, and equipment. Most leases include the option to renew, with renewal terms that can extend the lease term from one to five years or more. Right-of-use lease assets and lease liabilities are recognized at the commencement date based on the present value of the remaining lease payments over the lease term which includes renewal periods we are reasonably certain to exercise. Our leases do not contain any material residual value guarantees or material restrictive covenants. At ~~September~~June 30, ~~2021,~~2022, we do not have material lease commitments that have not commenced.

The lease term and discount rate at ~~September~~June 30, ~~2021~~2022 were as follows:

On a quarterly basis, we estimate what our effective tax rate will be for the full fiscal year and record a quarterly income tax provision based on the anticipated rate. As the year progresses, we refine our estimate based on the facts and circumstances, including discrete events, by each tax jurisdiction.

Our effective tax rate for the three and six months ended June 30, 2022 was 21% and 12%, respectively. The effective tax rate for the three and sixmonths ended ~~September~~June 30, 2021 was ~~26.0% compared to 23.7% for the~~ ~~three~~ ~~months ended~~ ~~September 30, 2020.~~ ~~The effective tax rate for the~~ ~~nine~~ ~~months ended~~ ~~September 30, 2021~~ ~~was 22.8% compared to 24.3% for the~~ ~~nine~~ ~~months ended~~ ~~September 30, 2020.~~ 38% and 30%, respectively. The primary ~~drivers~~driver of the change in the effective tax rate is attributable to ~~the PPP loan forgiveness being non-taxable and additional valuation allowance created from anticipated temporary differences. There are also discrete items related~~a US loss compared to ~~an IRS exam and return to provision adjustments~~income from the ~~2020~~ ~~tax return. It is more likely than~~ ~~not~~ ~~an amount payable will be due at an estimated~~ ~~$44k~~ ~~for the IRS exam. A reserve has been set up for the anticipated adjustment. We recorded an income tax expense of~~ ~~$646k~~ ~~and~~ ~~$638k~~ ~~for the~~ ~~nine~~ ~~months ended~~ ~~September 30, 2021~~ ~~and~~ ~~2020,~~ ~~respectively.~~foreign entities.

During the first ~~nine~~six months of 2021, we recorded restructuring charges of ~~$319~~$296 related to the consolidation of our production facilities and closure of our Merrifield, Minnesota facility. With the Merrifield closure, we shifted wire and cable assembly, system-level assembly and printed circuit board (PCB) manufacturing to Nortech’s other Minnesota locations. NaN amounts were accrued for the period ended ~~September 30, 2021.~~ We ~~reduced our workforce by approximately 42 employees as a result of this facility closure.~~

~~The sale of the Merrifield facility was completed in~~ ~~July 2021.~~ ~~We recognized~~had a gain on ~~the~~ sale of assets ~~related to~~of $15 and $94 in the ~~restructure of $93 and $176 for the~~ ~~three~~ ~~and~~ ~~nine~~six months ended ~~September~~June 30, 2022 and 2021,~~respectively.~~ respectively, related to the sale of machinery and equipment. There were no restructuring charges or amounts accrued in the six months ended June 30, 2022.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law providing numerous tax provisions and other stimulus measures, including an employee retention credit (“ERC”), which is a refundable tax credit against certain employment taxes. The Taxpayer Certainty and Disaster Tax Relief Act of 2020 and the American Rescue Plan Act of 2021 extended and expanded the availability of the ERC.

At June 30, 2022 and December 31, 2021, the Company has ERC benefits of $5,209 within Employee Retention Credits Receivable on the condensed consolidated balance sheet.

~~During the~~ ~~nine~~ ~~months ended~~ ~~September 30, 2021,~~ ~~we did business with Printed Circuits, Inc. which was 90% owned by the Kunin family until late~~ ~~2020.~~ ~~The Kunin family owns a majority of our stock. We had payments totaling $18 and $72 during the~~ ~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~September 30, 2021,~~ ~~respectively, and $0 and $28 for the~~ ~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~September 30, 2020,~~ respectively, to Printed Circuits, Inc. The Company believes that these transactions are on terms comparable to those that the Company could reasonably expect in an arm's length transaction with an unrelated ~~third~~ ~~party.~~

David Kunin, our Chairman, is a minority owner of Abilitech Medical, Inc. Mr. Kunin also was a consultant to Abilitech, which relationship ended on March 1, 2021. ~~During~~ ~~2020,~~ ~~Mr. Kunin earned $16 as a consultant to Abilitech.~~ In the three and sixmonths ended ~~September~~June 30, ~~2021~~2022, ~~and~~ ~~2020,~~Abilitech paid the Company ~~$316~~$163 and ~~$59,~~$217, respectively, ~~and in~~for delivery of medical products. In the ~~nine~~three and six months ended ~~September~~June 30, 2021, ~~and~~ ~~2020,~~Abilitech paid the Company ~~$1,056~~$472 and ~~$668,~~$740, respectively for the delivery of medical products. The Company believes that transactions with Abilitech are on terms comparable to those that the Company could reasonably expect in an arm's length transaction with an unrelated third party.

David Kunin, our Chairman, is a ~~small~~ minority owner (less than 10%) of Marpe Technologies, LTD an early-stage medical device company dedicated to the early detection of skin cancer through full body scanners. Mr. Kunin is also a member of the Board of Directors of Marpe Technologies. The Company worked with Marpe Technologies to apply for a grant from the Israel-United States Binational Industrial Research and Development Foundation, a legal entity created by Agreement between the Government of the State of Israel and the Government of the United States of America (“BIRD Foundation”). The parties were successful in receiving approval for a $1,000 conditional grant. The Company and Marpe Technologies will each receive ~~$500~~$500 from the BIRD Foundation and, among other obligations under the grant, each is required to contribute $500 to match grant funds from the BIRD Foundation. The Company will meet its obligation by providing certain services at cost or ~~with respect to administrative services at~~ no cost to Marpe Technologies. The total value of the contribution will not exceed ~~$500.~~ $500; the Company has contributed $182 as of June 30, 2022. The Company will receive a ~~10-year~~10-year exclusive right to manufacture the products of Marpe Technologies. There can be no assurances that Marpe Technologies’ medical device will be commercially successful, that Marpe Technologies will be successful in raising additional funds to finance its operations or, if commercially successful, the Company will recoup the value of services provided to Marpe for which is not fully paid. The transactions between the Company and Marpe Technologies have been approved by the Audit Committee pursuant to the Company Related-Party Transactions Policy. ~~As of~~During the ~~September~~six months ended June 30, ~~2021,~~2022, we ~~have received a $100 deposit, incurred expenses of $82 and~~ recognized revenue of ~~$78 from Marpe.~~$113. There was 0 revenue recognized for the six months ended June 30, 2021. The Company believes that transactions with Marpe are on terms comparable to those that the Company could reasonably expect in an arm’s length transaction with an unrelated third party.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

We are a ~~Maple Grove,~~ Minnesota, United States based full-service ~~electronics~~global EMS contract manufacturer in the Medical, Aerospace & Defense and Industrial markets offering a full range of value-added engineering, technical and manufacturing services ~~(“EMS”) contract manufacturer of~~and support including project management, design, testing, prototyping, manufacturing, supply chain management and post-market services. Our products are complex electromedical and electromechanical products including medical devices, wire and cable assemblies, printed circuit board assemblies, higher-level assemblies, and other box builds for a wide range of industries. We ~~provide value added engineering services~~serve three major markets within the EMS industry: Aerospace and ~~technical support including design, testing, prototyping~~Defense, Medical, and ~~supply chain management to customers mainly in~~ the ~~medical, aerospace~~Industrial market which includes industrial capital equipment, transportation, vision, agriculture, oil and ~~defense, and industrial equipment markets.~~gas. We maintain facilities in Bemidji, Blue Earth, Mankato, and Milaca, Minnesota; Monterrey, Mexico; and Suzhou, China. All of our facilities are certified to one or more of the ISO/AS standards, including 9001, AS9100 and 13485, with most having additional certifications based on the needs of the customers they serve.

Global Pandemic
~~In March 2020, the World Health Organization recognized the outbreak of a novel coronavirus (“COVID-19”) as a pandemic. While the~~

The COVID-19 pandemic ~~has had an~~continued to impact on our ~~operations, we have been able to continue to operate our manufacturing facilities~~business in the first six months of 2022, primarily by continued supply chain disruptions and provide essential services to our customers. Additionally, in an effort to protect the health and safety of our employees and in compliance with state regulations, we have instituted a work-from-home policy for employees who can perform their job functions offsite, implemented social distancing requirements and other measures to allow manufacturing and other personnel essential to production to continue work within our manufacturing facilities.

delays. The full extent to which COVID-19 will directly or indirectly impact our business, financial condition, and results of operations will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets. The ultimate impact of COVID-19 depends on factors beyond our knowledge or control, including the duration and severity of the outbreak, as well as third-party actions taken to contain its spread and mitigate its public health effects. As a result, we are unable to estimate the extent to which COVID-19 will negatively impact our financial results or liquidity.

We will continue to assess the current and potential impacts of the COVID-19 pandemic on our business, financial condition, and results of operations. We actively manage our cash and working capital to preserve adequate liquidity and ensure that our business can continue to operate during these uncertain times.

~~Facility Consolidation~~
To further improve operational efficiencies and lower overhead costs, the Company approved on August 7, 2020, the closure of our Merrifield, Minnesota, production facility, shifting wire and cable assembly, system-level assembly and printed circuit board (PCB) manufacturing to Nortech’s other Minnesota locations. The Merrifield production facility consolidation was completed in the first quarter of 2021 and impacted approximately 42 employees, who were offered positions at other Nortech facilities in Minnesota. We entered into an agreement on February 23, 2021 with a third-party agent to sell our facility in Merrifield, MN and some related assets. The sale closed in the third quarter of 2021.

~~Paycheck Protection Program (PPP) and Employee Retention Credit (ERC)~~
In the third quarter of 2021, we applied for forgiveness for the $6.1 million Promissory Note under the PPP. We will continue to treat this Promissory Note as debt until forgiveness is granted, any principal and interest amounts outstanding after the determination of amounts forgiven will be repaid on a monthly basis.

In addition, we applied for the ERC for qualified wages paid in the first and second quarters of 2021 and expect to receive approximately $5.2 million in fiscal 2021 or 2022. The ERC was recorded as a reduction of the associated payroll and benefit costs on the consolidated statements of operations for the three and nine months ended September 30, 2021 and as Employee Retention Credit Receivable on the consolidated balance sheet at September 30, 2021 (see Note 1.)

The following table presents statements of operations data as percentages of total net sales for the periods indicated:

Net sales for the three months ended June 30, 2022 and 2021 were ~~$29.5~~$32.5 and $30.2 million, ~~in the third quarter of 2021, as compared to $26.4 million in the third quarter of the prior year,~~respectively, an increase of ~~$3.1~~$2.3 million or ~~11.7%~~8%. Net sales for the six months ended June 30, 2022 and 2021 were $63.2 million and $52.3 million, respectively, an increase of $11.0 million or 21.0%. The ~~increase was~~three and six month increases were driven ~~primarily~~ by ~~net sales~~increased demand as well as price increases to counteract higher material and labor cost. We have also taken actions to scale the ~~industrial market which increased by $3.4 million or 58.0% in~~direct labor workforce and strengthen the ~~third quarter of 2021 as compared to the third quarter of 2020.~~supply chain for parts.

Net sales ~~were $81.7 million~~to medical and defense customers increased compared to prior year for both the three and six month periods ended June 30, 2022. Sales to industrial customers decreased in the ~~nine~~three months ended ~~2021, as compared to $80.3 million~~June 30, 2022 versus the same period in the prior year an increase of $1.4 million or 1.8%. Net sales results were varied by markets. The medical market increased by $2.8 million, or 6.2% and the industrial market increased by $3.8 million of sales or 17.2%, while net sales from the aerospace and defense markets decreased $5.0 million or 32%.primarily due to supply chain challenges for electronic components.

Net sales by our major EMS industry markets for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020~~2021 were as follows (in ~~thousands)~~millions):

~~Net sales by timing of transfer of goods and services for the three and nine months ended September 30, 2021 is as follows (in thousands):~~

Net sales by timing of transfer of goods and services for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2022 is as follows (in ~~thousands)~~millions):

Net sales by timing of transfer of goods and services for the three and six months ended June 30, 2021 is as follows (in millions):

Our 90-day shipment backlog as of ~~September~~June 30, ~~2021~~2022 was ~~$38.9~~$35.9 million, ana 1.2% increase ~~of 12.0%~~ from the beginning of the quarter and a ~~68.3%~~3.5% increase ~~as compared to the prior year. Backlog for our medical customers has increased 4.2%~~ from ~~the beginning of the quarter and increased 71.3% from the prior year. The aerospace and defense backlog increased 43.3% from the beginning of the quarter and 26.7% from the prior year.~~June 30, 2021. Our ~~industrial customers’ backlog increased 7.9% from the beginning of the quarter and increased 119.3% from the prior year. This~~ backlog consists of firm purchase orders we expect to ship in the next 90 days, with any remaining amounts to be transferred within 180 days.

Our 90-day shipment backlog by market has remained relatively constant when compared to the prior quarter end and the same period of the prior year. 90-day shipment backlog by our major ~~EMS~~ industry markets are as follows (in ~~thousands)~~millions):

Our 90-day backlog varies due to order size, manufacturing delays, contract terms and conditions and timing from customer delivery schedules and releases. These variables cause inconsistencies in comparing the backlog from one period to the next. Our total shipment backlog was ~~$78.6~~$106.2 million ~~at September~~and $71.5 million as of June 30, 2022 and 2021, ~~compared to $45.7~~respectively. This backlog contains the contract asset value of $9.1 million ~~at September 30, 2020.~~which have been recognized as revenue.

Gross profit as a percent of net sales was 15.4% and 11.9% for the three months ended ~~September~~June 30, ~~2021~~2022 and ~~2020 was 27.3% and 7.4%,~~2021, respectively. Gross profit as a ~~percentage~~percent of net sales was 14.3% and 9.9% for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020 was 16.1% and 9.9%,~~2021, respectively. The gross profit improvement ~~relates~~was primarily driven by price increases in response to ~~the $4.7 million reduction in payroll~~material and ~~medical expenses related to the ERC and~~labor cost inflation as well as higher production volume which increased ~~utilization as a result of the increase in sales.~~plant utilization.

Selling expenses for the three months ended ~~September~~June 30, 2022 and 2021 ~~and 2020 was $0.4~~were $1.0 million or ~~1.5%~~2.9% of sales and $0.6 million or ~~2.3%~~1.9% of sales, respectively. Selling ~~expense~~expenses for the ~~nine~~six months ended ~~September~~June 30, 2022 and 2021 ~~and 2020 was $1.7~~were $1.8 million or ~~2.1%~~2.8% of sales and ~~$1.9~~$1.3 million or ~~2.4%~~2.5% of sales, respectively. The ~~decrease~~increase in selling expense for ~~both~~ the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 compared to the same periods inof the prior year relates ~~primarily~~ to an increase in headcount to support the ~~reduction in payroll and medical expenses of $0.1 million due to the ERC.~~increased sales.

General and administrative expenses for the three months ended ~~September~~June 30, 2022 and 2021 ~~and 2020~~ were ~~$2.0~~$2.7 million or ~~6.9%~~8.2% of sales and ~~$2.5~~$2.4 million or ~~9.4%~~8.0% of sales, respectively. General and administrative expenses for the ~~nine~~six months ended ~~September~~June 30, 2022 and 2021 ~~and 2020~~ were ~~$7.2~~$5.4 million or ~~8.9%~~8.5% of sales and ~~$6.7~~$5.2 million or ~~8.3%~~10.0% of sales, respectively. ~~The decrease in general~~General and administrative expenses for the three and six months ended ~~September~~June 30, ~~2021~~2022 were held relatively flat compared to the same ~~period~~periods of ~~2020 relates primarily~~the prior year, and are generally fixed in nature.

Restructuring charges for the three and six months ended June 30, 2021 were $0.1 million and $0.3 million, respectively. There were no restructuring charges for the three and six months ended June 30, 2022. The restructuring charges relate to the ~~reduction in payroll and medical expenses~~closure of ~~$0.4 million related to~~ the ~~ERC. The increase in general and administrative expenses for the nine months ended September 30, 2021 compared to the same period of 2020 relates primarily to an increase in professional service fees.~~Merrifield facility during 2021.

Research and development expenses were $0.4 million or 1.1% of net sales for the three months ended ~~September~~June 30, ~~2021 were $0.1~~2022 and $0.7 million or ~~0.5%~~1.1% of ~~sales.~~net sales for the six months ended June 30, 2022. Research and development expenses for ~~the nine months ended September 30, 2021 were $0.3 million or 0.4% of sales. There were minimal to no research and development expenses for~~both the three and ~~nine~~six months ended ~~September~~June 30, ~~2020.~~2021 was $0.2 million.

~~Restructuring charges~~Income from operations for the three months ended ~~September~~June 30, ~~2021 were approximately $23 thousand or 0.1% of sales. Restructuring charges for the nine months ended September 30, 2021~~2022 was ~~$0.3~~$1.0 million ~~or 0.4% of sales. There were no restructuring charges~~compared to $0.4 million for the three ~~and nine~~ months ended ~~September~~June 30, ~~2020.~~2021. Income from operations for the six months ended June 30, 2022 was $1.2 million compared to a loss from operations of $1.8 million for the six months ended June 30, 2021. The ~~restructuring charges are due~~three and six month improvements compared to the ~~closure~~same periods of the ~~Merrifield facility.~~

~~Loss on Abandonment~~prior year were driven by the increase in sales and gross margin as a percent of ~~Intangible Asset~~sales.

Interest expense was $0.1 million for both the three ~~and nine~~ months ended ~~September~~June 30, ~~2021 were approximately $0.6 million. There were no abandonment charges~~2022 and 2021. Interest expense was $0.2 million for both the ~~three and nine~~six months ended ~~September~~June 30, ~~2020. The charges relate to the abandonment of the Devicix tradename.~~2022 and 2021.

Our effective tax rate for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 was ~~26.0%~~21% and ~~22.8%~~12%, ~~respectively, and the~~respectively. The effective tax rate for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 was ~~22.8%~~38% and ~~24.3%~~30%, respectively. The primary driver of the change in the effective tax rate is attributable to a US loss compared to income from the foreign entities.

Net income for the three months ended June 30, 2022 was $719 thousand or $0.27 per basic common share and ~~net loss for the nine months ended September 30, 2021 was $3.6 million and $2.2 million, respectively.~~$0.25 per diluted common share. Net income for the three ~~and nine~~ months ended ~~September~~June 30, ~~2020~~2021 was ~~$2.0 million.~~$179 thousand or $0.07 per basic common share and $0.06 per diluted common share. Net income for the ~~three and nine~~six months ended ~~September~~June 30, 2022 was $857 thousand or $0.32 per basic common share and $0.30 per diluted common share. Net loss for the six months ended June 30, 2021 was ~~affected by the reduction in payroll~~($1,375) thousand or ($0.52) per basic and ~~benefit expense for the ERC, while the three and nine months ended September 30, 2020 included a $3.8 million gain on sale of assets.~~diluted common share.

Our 2021 sales were impacted by the ongoing COVID-19 pandemic and the related supply chain and workforce shortages. Due to the inherent uncertainty of this evolving situation, we are unable at this time to predict the likely impact of the COVID-19 pandemic on our future operations which has led to indicators of an inability to continue as a going concern. However, these indicators have been mitigated by our focus on reducing costs and minimizing capital expenditures. In addition, weWe believe that our existing financing arrangements, anticipated cash ~~provided by~~flows from operations, ~~funds available under the credit agreement with Bank of America, N.A. (BofA),~~ funds expected to be received for the ERC and cash on hand will be ~~adequate~~sufficient to ~~meet~~satisfy our ~~liquidity~~working capital needs ~~including working capital,~~for the next twelve months, capital expenditures and debt ~~payment obligations.~~repayments.

Net cash used by operating activities for the nine months ended September 30, 2021 was $2.9 million. Increases in working capital due to the higher sales and backlog drove the use of cash by operating activities, primarily in increased inventory of $5.8 million.

We have a credit agreement with Bank of America ~~(BofA)~~ which was entered into on June 15, ~~2017 and amended on December 29,~~ 2017 and provides for a line of credit arrangement of $16.0 million that expires on June 15, ~~2022. The credit arrangement also has a $5.0 million real estate term note outstanding with a maturity date of June 15, 2022. We expect to extend the agreement past June 15, 2022.~~2026.

~~Both~~Under the amended Bank of America credit agreement signed December 31, 2021, the line of credit ~~and real estate term notes are~~is subject to ~~fluctuations~~variations in the ~~LIBOR rates.~~Bloomberg Short-Term Bank Yield (BSBY) index rate. Our line of credit bears interest at a weighted-average interest rate of 3.9% and 3.5% as of June 30, 2022 and December 31, 2021, respectively. We had borrowings on our line of credit of $11.4 million and $9.0 million outstanding as of June 30, 2022 and December 31, 2021, respectively. There are no subjective acceleration clauses under the credit agreement that would accelerate the maturity of our outstanding borrowings. The line of credit is shown net of debt issuance costs of $50 thousand and ~~real estate term notes~~$58 thousand on the consolidated balance sheet for the periods ended June 30, 2022 and December 31, 2021, respectively.

The line of credit with ~~BofA contain~~Bank of America contains certain covenants which, among other things, require us to adhere to regular reporting requirements, abide by annual shareholder dividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures. ~~The availability under our line is subject to borrowing base requirements, and advances are at the discretion of the lender. The line of credit is secured by substantially all of our assets.~~

The Bank of America Credit Agreement provides for, among other things, a Fixed Charge Coverage Ratio of not less than 1.0 to 1.0 for the twelve months ~~ending December 31, 2020 and~~ended at each Fiscal Quarter end ~~thereafter~~ subject only during a trigger period commencing when our availability under our line is less than $2,000 until availability is above that amount for 30 ~~days due to amendment to our agreement dated~~days. As of June 30, 2022 the Company was in ~~December of 2020. The Company met the covenants for the period ended September 30, 2021.~~compliance with its covenants.

~~The availability under the line is subject to borrowing base requirements, and advances are at the discretion of the lender.~~ At ~~September~~June 30, ~~2021, we had outstanding advances of $6.0 million and~~2022, we had unused availability under our line of credit of ~~$5.8~~$4.2 million supported by our borrowing base. ~~We believe~~The line is secured by substantially all of our ~~financing arrangements and cash flows to be provided by operations will be sufficient to satisfy our future working capital needs.~~

~~On April 15, 2020, we entered into a Promissory Note with Bank of America, N.A. (the “Promissory Note”), which provides for an unsecured loan of $6.1 million pursuant to~~assets. In the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security Act and applicable regulations (the “CARES Act”) of which; funds were received on April 22, 2020. The Promissory Note has a term of 2 years with a 1% per annum interest rate. Payments are deferred for 6 months from the date of the Promissory Note and we can apply for forgiveness of the Promissory Note after 60 days. Forgiveness of the Promissory Note will be determined in accordance with the provisions of the Cares Act and applicable regulations. We applied for forgiveness in the thirdfirst quarter of ~~2021, any principal and interest amounts outstanding after~~2022, we amended our credit agreement to include the ~~determination~~Employee Retention Credit Receivable as security in our line of ~~amounts forgiven will be repaid on a monthly basis.~~ credit which improved our unused availability.

We have not engaged in any off-balance sheet activities as defined in Item 303(a)(4) of Regulation S-K.

Our significant accounting policies and estimates are summarized in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021. Some of our accounting policies require us to exercise significant judgment in selecting the appropriate assumptions for calculating financial estimates. Such judgments are subject to an inherent degree of uncertainty. These judgments are based on our historical experience, known trends in our industry, terms of existing contracts and other information from outside sources, as appropriate. Actual results could differ from these estimates.

Those statements in the foregoing report that are not historical facts are forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

The factors identified above are believed to be important factors (but not necessarily all of the important factors) that could cause actual results to differ materially from those expressed in any forward-looking statement made by us. Discussion of these factors is also incorporated in Part I, Item 1A, “Risk Factors,” and should be considered an integral part of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Unpredictable or unknown factors not discussed herein could also have material adverse effects on forward-looking statements. All forward-looking statements included in this Form ~~10-Q~~10-K are expressly qualified in their entirety by the forgoing cautionary statements. We undertake no obligations to update publicly any forward-looking statement (or its associated cautionary language) whether as a result of new information or future events.

Please refer to forward-looking statements and risks as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2020.~~2021.

In accordance with Rule 13a-15(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this Quarterly Report on Form 10-Q, our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act). These controls and procedures are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is (1) recorded, processed, summarized and reported in a timely manner, and (2) accumulated and communicated to management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon their evaluation of these disclosure controls and procedures as of the date of the evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective.

There was no change in our internal control over financial reporting during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

We are subject to various legal proceedings and claims that arise in the ordinary course of business.

We are affected by the risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition or operating results or could cause our actual results to differ materially from our expectations are described in our annual report on Form 10-K for the fiscal year ended under the heading “Part I – Item 1A.Risk Factors.” ~~Other than as noted below, there~~There have been no material changes in the risk factors from those disclosed in the Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021.

As of ~~September~~June 30, ~~2021,~~2022, our share repurchase program has expired, and no additional amounts are available for repurchase.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(UNAUDITED)
(IN THOUSANDS, EXCEPT SHARE DATA)

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(UNAUDITED)
(IN THOUSANDS)

	Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding - January 1, 2021		362,640		$	3.96
Granted		27,000			6.14
Exercised		(13,400	)		3.43
Cancelled		(10,340	)		3.42
Outstanding - September 30, 2021		365,900		$	4.15		7.25	$	2,688
Exercisable - September 30, 2021		180,500		$	3.75		6.56	$	1,398

	Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding - January 1, 2022		387,500		$	4.57
Granted		87,000			11.10
Exercised		(12,000	)		3.41
Cancelled		(4,400	)		3.36
Outstanding - June 30, 2022		458,100		$	5.82		6.97	$	3,326
Exercisable - June 30, 2022		222,700		$	3.93		6.12	$	2,038

	THREE MONTHS						NINE MONTHS
	ENDED						ENDED
	SEPTEMBER 30,						SEPTEMBER 30,
	2021			2020			2021			2020

Net Sales	$	29,452		$	26,362		$	81,706		$	80,263

Cost of Goods Sold		21,411			24,400			68,519			72,336

Gross Profit		8,041			1,962			13,187			7,927

Operating Expenses
Selling Expenses		449			594			1,741			1,945
General and Administrative Expenses		2,045			2,480			7,247			6,654
Research and Development		141			0			348			0
Restructuring		23			0			319			0
Loss on Abandonment of Intangible Asset		560			0			560			0
Gain on Sale of Assets		(93	)		(3,821	)		(176	)		(3,821	)
Total Operating Expenses		3,125			(747	)		10,039			4,778

Income From Operations		4,916			2,709			3,148			3,149

Other Expense
Interest Expense		(112	)		(126	)		(314	)		(526	)

Income Before Income Taxes		4,804			2,583			2,834			2,623

Income Tax Expense		1,247			612			646			638

Net Income	$	3,557		$	1,971		$	2,188		$	1,985

Net Income Per Common Share - Basic	$	1.33		$	0.74		$	0.82		$	0.75

Weighted Average Number of Common Shares Outstanding - Basic		2,665,682			2,657,530			2,662,066			2,657,530

Net Income Per Common Share - Diluted	$	1.24		$	0.73		$	0.78		$	0.74

Weighted Average Number of Common Shares Outstanding - Diluted		2,880,073			2,703,029			2,806,958			2,670,984

Other Comprehensive Income
Foreign Currency Translation Gain (Loss)		(5	)		96			20			54
Comprehensive Income, Net of Tax	$	3,552		$	2,067		$	2,208		$	2,039

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE DATA)

	NINE MONTHS ENDED
	SEPTEMBER 30,
	2021			2020
Cash Flows From Operating Activities
Net Income	$	2,188		$	1,985
Adjustments to Reconcile Net Income to Net Cash
(Used In) Provided by Operating Activities
Depreciation and Amortization		1,506			1,703
Compensation on Stock-Based & Equity Awards		201			151
Change in Accounts Receivable Allowance		18			158
Change in Inventory Reserves		(959	)		398
Loss on Abandonment of Intangible Asset		560			0
Gain on Disposal of Property and Equipment		(176	)		(3,821	)
Changes in Current Operating Items
Accounts Receivable		1,686			2,430
Employee Retention Credit Receivable		(5,209	)		0
Inventories		(5,755	)		(567	)
Contract Assets		(2,246	)		325
Prepaid Expenses and Other Current Assets		(276	)		858
Income Taxes		708			0
Accounts Payable		2,901			(2,808	)
Accrued Payroll and Commissions		1,537			(621	)
Other Accrued Liabilities		464			(290	)
Net Cash Used In Operating Activities		(2,852	)		(99	)
Cash Flows from Investing Activities
Proceeds from Sale of Property and Equipment		626			6,019
Purchase of Intangible Asset		(49	)		(25	)
Purchases of Property and Equipment		(1,198	)		(397	)
Net Cash (Used In) Provided By Investing Activities		(621	)		5,597
Cash Flows from Financing Activities
Net Change in Line of Credit		2,681			(7,542	)
Proceeds from Long-term Debt		0			6,077
Principal Payments on Long-Term Debt		(873	)		(2,567	)
Principal Payments on Finance Leases		(492	)		(432	)
Stock Option Exercises		36			0
Net Cash Provided By (Used In) Financing Activities		1,352			(4,464	)

Net Change in Cash		(2,121	)		1,034
Cash - Beginning of Period		3,564			660

Cash - Ending of Period	$	1,443		$	1,694

Reconciliation of cash and restricted cash reported within the condensed consolidated balance sheets
Cash	$	444		$	328
Restricted Cash		999			1,366
Total cash and restricted cash reported in the condensed consolidated statements of cash flows	$	1,443		$	1,694

Supplemental Disclosure of Cash Flow Information:
Cash Paid During the Period for Interest	$	220		$	526
Cash Paid (Refunded) During the Period for Income Taxes	$	(114	)	$	262

Supplemental Noncash Investing and Financing Activities:
Property and Equipment Purchases in Accounts Payable	$	0		$	6
Property Acquired under Operating Lease	$	858		$	4,685
Equipment Acquired under Finance Lease	$	0		$	395

	September 30,			December 31,			June 30,			December 31,
	2021			2020			2022			2021
Raw Materials	$	19,673		$	14,865		$	21,764		$	18,492
Work in Process		1,683			969			1,793			1,678
Finished Goods		485			242			608			562
Reserves		(1,199	)		(2,159	)		(1,195	)		(1,298	)

Total	$	20,643		$	13,917		$	22,970		$	19,434

	Customer Relationships			Trade Names			Patents		Total
Balance at January 1, 2020	$	651		$	631		$	56	$	1,338
Additions		0			0			20		20
Amortization		(144	)		(41	)		0		(185	)
Balance at December 31, 2020	$	507		$	590		$	76	$	1,173
Additions		0			0			50		50
Amortization		(109	)		(30	)		0		(139	)
Abandonment Loss		0			(560	)		0		(560	)
Balance at September 31, 2021	$	398		$	0		$	126	$	524

	Customer Relationships		Trade Names		Patents		Total
Balance at January 1, 2021	$	507	$	589	$	77	$	1,173
Additions		0		0		64		64
Amortization		147		29		0		176
Abandonment Loss		0		560		0		560
Balance at December 31, 2021		360		0		141		501
Additions		0		0		41		41
Amortization		71		0		0		71
Balance at June 30, 2022	$	289	$	0	$	182	$	471

	Three Months Ended				Nine Months Ended
	September 30, 2020				September 30, 2020
	Previously Reported		After Reclassification		Previously Reported		After Reclassification
Cost of Goods Sold	$	24,717	$	24,400	$	73,171	$	72,336
General and Administrative Expenses		2,164		2,480		5,819		6,654

Nine Months Ended September 30, 2021
Outstanding at January 1, 2021	$	5,899
Increase (decrease) attributed to:
Transferred to receivables from contract assets recognized		(5,140	)
Product transferred over time		7,387
Outstanding at September 30, 2021	$	8,145

Balance outstanding at December 31, 2021	$	8,698
Increase (decrease) attributed to:
Transferred to receivables from beginning contract assets		(8,360	)
Product transferred over time to ending contract assets		8,732
Balance outstanding at June 30, 2022	$	9,070

	Three Months Ended September 30, 2021
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market

Medical	$	13,762	$	2,933	$	282	$	16,977
Aerospace and Defense		2,883		144		65		3,092
Industrial		7,468		1,757		158		9,383
Total Net Sales	$	24,113	$	4,834	$	505	$	29,452

Year	Amount
Remainder of 2021	$	36
2022		145
2023		145
2024		72
Total	$	398

Year	Amount
Remainder of 2022	$	72
2023		145
2024		72
Total	$	289

	Balance Sheet Location	June 30, 2022		December 31, 2021
Assets
Operating lease assets	Operating lease assets	$	8,420	$	8,983
Finance lease assets	Property, plant and equipment		1,867		2,052

Total leased assets		$	10,287	$	11,035

	Operating Leases			Finance Leases			Total
Remaining 2022	$	871		$	293		$	1,164
2023		1,789			409			2,198
2024		1,507			357			1,864
2025		1,255			103			1,358
2026		1,217			115			1,332
Thereafter		7,066			0			7,066
Total lease payments	$	13,705		$	1,277		$	14,982
Less: Interest		(4,504	)		(96	)		(4,600	)
Present value of lease liabilities	$	9,201		$	1,181		$	10,382

	Three Months Ended June 30, 2021
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	12,776	$	3,050	$	244	$	16,070
Industrial		8,287		1,738		151		10,176
Aerospace and Defense		3,738		122		76		3,936
Total net sales	$	24,801	$	4,910	$	471	$	30,182

	Three Months Ended September 30, 2020
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market

Medical	$	10,960	$	1,853	$	1,405	$	14,218
Aerospace and Defense		5,525		16		665		6,206
Industrial		4,527		791		620		5,938
Total Net Sales	$	21,012	$	2,660	$	2,690	$	26,362

	Six Months Ended June 30, 2022
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	22,972	$	9,678	$	1,154	$	33,804
Industrial		13,459		3,987		675		18,121
Aerospace and Defense		10,046		761		497		11,304
Total net sales	$	46,477	$	14,426	$	2,326	$	63,229

	Nine Months Ended September 30, 2020
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market

Medical	$	35,835	$	4,454	$	2,464	$	42,753
Aerospace and Defense		14,160		396		953		15,509
Industrial		17,434		3,354		1,213		22,001
Total Net Sales	$	67,429	$	8,204	$	4,630	$	80,263

	Six Months Ended June 30, 2021
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	21,735	$	5,942	$	734	$	28,411
Industrial		12,917		3,075		403		16,395
Aerospace and Defense		6,802		384		262		7,448
Total net sales	$	41,454	$	9,401	$	1,399	$	52,254

	Three Months Ended June 30,		Three Months Ended June 30,
Lease Cost	2022		2021
Operating lease cost	$	578	$	589
Finance lease interest cost		17		21
Finance lease amortization expense		183		163
Total lease cost	$	778	$	773

	Six Months Ended June 30,		Six Months ended June 30,
Lease Cost	2022		2021
Operating lease cost	$	1,159	$	1,120
Finance lease interest cost		36		43
Finance lease amortization expense		365		326
Total lease cost	$	1,560	$	1,489

		September 30		December 31
	Balance Sheet Location	2021		2020
Assets
Operating Lease Assets	Operating Lease Assets	$	9,052	$	8,998
Finance Lease Assets	Property and Equipment, Net		1,841		2,330
Total Leased Assets		$	10,893	$	11,328

Liabilities
Current
Current Operating Lease Liabilities	Current Portion of Operating Lease Obligations	$	1,023	$	688
Current Finance Lease Liabilities	Current Portion of Finance Lease Obligations		613		660
Noncurrent
Long-Term Operating Lease Liabilities	Long-Term Operating Lease Obligations, Net		8,744		8,889
Long Term Finance Lease Liabilities	Long Term Finance Lease Obligations, Net		707		1,152
Total Lease Liabilities		$	11,087	$	11,389

	Operating Leases			Finance Leases			Total
Remaining 2021	$	433		$	185		$	618
2022		1,735			587			2,322
2023		1,737			333			2,070
2024		1,408			280			1,688
2025		1,205			26			1,231
Thereafter		8,283			0			8,283
Total Lease Payments	$	14,801		$	1,411		$	16,212
Less: Interest		(5,034	)		(91	)		(5,125	)
Present Value of Lease Liabilities	$	9,767		$	1,320		$	11,087

~~Weighted-Average Remaining Lease Term (Years)~~Weighted-average remaining lease term (years)
Operating ~~Leases~~leases	~~9.6~~9.2
Finance ~~Leases~~leases	2.6
~~Weighted-Average Discount Rate~~Weighted-average discount rate
Operating ~~Leases~~leases	~~7.8~~7.7	%
Finance ~~Leases~~leases	~~5.1~~5.2	%

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2022			2021			2022			2021
Net Sales		100.0	%		100.0	%		100.0	%		100.0
Cost of Goods Sold		84.6			88.1			85.7			90.1
Gross Profit		15.4			11.9			14.3			9.9

Selling Expenses		2.9			1.9			2.8			2.5
General and Administrative Expenses		8.2			8.0			8.5			10.0
R&D Expenses		1.1			0.7			1.1			0.4
Restructuring Charges		-			0.3			-			0.6
Gain on Sale of Property and Equipment		0.0			(0.3	)		0.0			(0.2	)
Income (Loss) from Operations		3.2			1.3			1.9			(3.4	)

Interest Expense		(0.4	)		(0.3	)		(0.3	)		(0.4	)
Income (Loss) Before Income Taxes		2.8			1.0			1.6			(3.8	)

Income Tax Expense (Benefit)		0.6			0.4			0.2			(1.2	)
Net (Loss) Income		2.2	%		0.6	%		1.4	%		(2.6	)%

	Three Months Ended September 30, 2020
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market		Three Months Ended June 30, 2022
									Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	10,960	$	1,853	$	1,405	$	14,218	$	13.2	$	4.8	$	0.6	$	18.6
Industrial										6.9		2.2		0.3		9.4
Aerospace and Defense		5,525		16		665		6,206		3.9		0.4		0.2		4.5
Industrial		4,527		791		620		5,938
Total Net Sales	$	21,012	$	2,660	$	2,690	$	26,362
Total net sales										24.0		7.4		1.1		32.5

	Shipment Backlog as of the Period Ended						Shipment Backlog as of the Period Ended
	September 30,		June 30,		September 30,		June 30		March 31		June 30
	2021		2021		2020		2022		2022		2021
Medical	$	19,666	$	18,879	$	11,483	$	20.9	$	19.7	$	18.9
Industrial								9.8		9.7		9.8
Aerospace and Defense		8,568		5,981		6,764		5.2		6.0		6.0
Industrial		10,657		9,874		4,860
	$	38,891	$	34,734	$	23,108
Total 90-Day Backlog							$	35.9	$	35.4	$	34.7

	♦	Volatility in the marketplace which may affect market supply, demand of our products, labor rates or currency exchange rates;
	♦	Supply chain disruption and ~~unreliability due to COVID-19;~~ unreliability;
	♦	Lack of supply of sufficient human resources to produce our products;
	♦	Increased competition from within the EMS industry or the decision of OEMs to cease or limit outsourcing;
	♦	Changes in the reliability and efficiency of our operating facilities or those of third parties;
	♦	Increases in certain raw material costs such as copper and oil;
	♦	Commodity and energy cost instability;
	♦	Risks related to FDA noncompliance;
	♦	The loss of a major customer;
	♦	General economic, financial and business conditions that could affect our financial condition and results of operations;
	♦	Increased or unanticipated costs related to compliance with securities and environmental regulation;
	♦	Disruption of global or local information management systems due to natural disaster or cyber-security incident;
	♦	Outbreaks of epidemic, pandemic, or contagious diseases, such as the recent novel coronavirus that affect our operations, our customers' operations or our suppliers' operations.

	31.2*
	31.2*	Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended.

	32*
	32*	Certification of the Chief Executive Officer and Chief Financial Officer, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

	101*
	101*	Financial statements from the quarterly report on Form 10-Q for the quarter ended ~~September~~June 30, ~~2021,~~2022, formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss, (iii) Condensed Consolidated Statements of Cash Flows, and (iv) the Condensed Notes to Condensed Consolidated Financial Statements.

	~~104~~
	104	Cover Page Interactive Data File ~~(embedded within the~~(formatted as Inline XBRL and contained in Exhibit 101) .

~~Nortech Systems Incorporated and Subsidiaries~~ Date: August 9, 2022	by /s/ Jay D. Miller
~~---------------------------------------------------------~~

	Jay D. Miller
	Chief Executive Officer and President
	Nortech Systems Incorporated

Date: ~~November 10, 2021~~ August 9, 2022		by /s/ ~~Jay~~Christopher D. ~~Miller~~Jones

		~~Jay~~Christopher D. ~~Miller~~	Jones
		~~Chief Executive Officer and President~~
		~~Nortech Systems Incorporated~~

~~Date: November 10, 2021~~		by ~~/s/ Christopher D. Jones~~

		~~Christopher D. Jones~~
		Vice President and Chief Financial Officer
		Nortech Systems Incorporated

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(IN THOUSANDS)